CARM Stock Crashes 99% on NASDAQ: Carisma Therapeutics Faces Severe Decline

CARM stock has collapsed to historic lows, trading at just $0.0001 per share on NASDAQ as of April 23, 2026. Carisma Therapeutics, Inc., a Philadelphia-based biopharmaceutical company, has experienced a devastating -99.09% decline in a single trading session. The company develops chimeric antigen receptor (CAR) macrophages for solid tumor treatment and maintains a strategic partnership with Moderna Inc. With a market cap of just $41,845 and trading volume of only 1,900 shares, CARM stock represents one of the most distressed equities in the healthcare sector today. This extreme deterioration raises serious questions about the company’s viability and future prospects.

CARM Stock Price Collapse and Market Metrics

Carisma Therapeutics stock has reached penny stock status with shares trading at $0.0001, down from a previous close of $0.011. The intraday loss of -99.09% represents one of the most severe single-day declines in biotech history. Year-to-date, CARM stock has fallen -97.67%, while the one-year decline stands at -99.53%. The 52-week range shows a devastating drop from a high of $1.27 to a low of $0.001.

Trading Activity and Liquidity Crisis

Trading volume has dried up significantly, with only 1,900 shares changing hands compared to an average daily volume of 91,814 shares. This represents just 11.2% of normal trading activity. The market cap has shrunk to a mere $41,845, making CARM one of the smallest publicly traded companies. With such minimal liquidity, investors face extreme difficulty executing trades at reasonable prices. The bid-ask spread likely remains wide, creating additional friction for any remaining shareholders attempting to exit positions.

Financial Health and Valuation Concerns

Meyka AI rates CARM with a grade of B+, suggesting a buy rating despite current distress. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, the fundamentals paint a troubling picture. The company shows negative working capital of -$942,000 and negative shareholders’ equity of -$0.0207 per share.

Profitability and Cash Flow Analysis

CARM stock trades at an extremely low price-to-earnings ratio of 0.05, but this metric is misleading given the company’s financial distress. Net profit margin stands at 15.28%, yet the company burns cash with operating cash flow of -$0.54 per share. Free cash flow is equally negative at -$0.54 per share, indicating the company cannot sustain operations without external funding. Return on equity is deeply negative at -28.86%, reflecting shareholder value destruction. Track CARM on Meyka for real-time updates on this deteriorating situation.

Market Sentiment and Technical Breakdown

Technical indicators reveal extreme oversold conditions across multiple metrics. The Relative Strength Index (RSI) sits at 13.06, well below the 30 oversold threshold, indicating severe selling pressure. The Commodity Channel Index (CCI) reads -200.30, another extreme oversold signal. Williams %R stands at -99.73, suggesting maximum downward momentum.

Trading Activity and Liquidation Signals

The Money Flow Index (MFI) registers 19.53, confirming oversold conditions with weak buying interest. On-Balance Volume (OBV) shows -1,493,354, indicating persistent selling pressure. The Average True Range (ATR) of 0.01 reflects minimal price movement due to illiquidity. Rate of Change (ROC) at -99.40% confirms the catastrophic price deterioration. These technical signals suggest capitulation selling and potential forced liquidations from distressed holders.

Analyst Consensus and Future Outlook

Despite the stock’s collapse, one analyst maintains a buy rating on CARM stock, though this appears disconnected from current market realities. The consensus rating of 4.00 (on a scale where lower is more bullish) reflects minimal analyst coverage. No price target consensus exists, leaving investors without guidance on fair value.

Company Operations and Strategic Position

Carisma Therapeutics employs 46 full-time staff and maintains headquarters in Philadelphia, Pennsylvania. The company’s partnership with Moderna Inc. represents a significant strategic asset, though recent developments suggest this collaboration may face challenges. Revenue per share stands at $1.26, but the company’s ability to generate sustainable revenue remains questionable given negative cash flows. The company’s focus on CAR macrophage technology for solid tumors represents a promising therapeutic approach, yet execution risks appear substantial given current financial constraints.

Final Thoughts

CARM stock has collapsed to $0.0001, creating severe liquidity challenges and making it nearly impossible for investors to exit positions. The company faces uncertain survival without major capital infusion or restructuring, despite promising CAR macrophage technology and a Moderna partnership. Extreme oversold conditions suggest capitulation selling has peaked. CARM is a highly speculative, distressed security suitable only for investors with extreme risk tolerance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.